StockNews.com lowered shares of DexCom (NASDAQ:DXCM – Free Report) from a buy rating to a hold rating in a research report report published on Saturday. A number of other analysts have also weighed in ...

DexCom (NASDAQ:DXCM – Free Report) had its price objective boosted by Wells Fargo & Company from $80.00 to $90.00 in a ...

In what makes Abbott Laboratories a serious competitor is the much lower price one has to pay for FreeStyle Libre - in comparison to Dexcom's G6 (or G7) and also in comparison to Medtronic's Guardian.

We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Jefferies analyst Matthew Taylor maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Medicare's decision to reimburse for the G6 and G7 is a favorable ... Meaningful innovation should allow Dexcom to compete on other dimensions than price. Unlike most diagnostics where it is ...

DexCom's Q2 earnings report was disastrous, revealing internal sales channel issues and competitive pressures, leading to a Hold rating and lowered price targets. The company's reliance on channel ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of ... DexCom G5 Mobil, DexCom G6, and DexCom Share.

The introduction of sensors like G6 and G7 in international markets also fueled revenue growth. Dexcom anticipates strong ... tickers "Most Likely for Early Price Pops." Since 1988, the full ...